NASDAQ:RGEN Repligen - RGEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. $160.25 -2.39 (-1.47%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$157.11▼$161.4350-Day Range$160.25▼$198.1052-Week Range$137.21▼$262.26Volume599,138 shsAverage Volume579,127 shsMarket Capitalization$8.90 billionP/E Ratio49.31Dividend YieldN/APrice Target$216.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Repligen MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside35.3% Upside$216.86 Price TargetShort InterestBearish8.01% of Float Sold ShortDividend StrengthN/ASustainability-1.30Upright™ Environmental ScoreNews Sentiment0.30Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth29.55%From $2.64 to $3.42 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.59 out of 5 starsMedical Sector202nd out of 989 stocksBiological Products, Except Diagnostic Industry30th out of 166 stocks 3.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $216.86, Repligen has a forecasted upside of 35.3% from its current price of $160.25.Amount of Analyst CoverageRepligen has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.01% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Repligen has recently increased by 9.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 69.02% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.30. Previous Next 2.4 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Repligen this week, compared to 3 articles on an average week.Search InterestOnly 24 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows6 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of Repligen is held by insiders.Percentage Held by Institutions91.00% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 29.55% in the coming year, from $2.64 to $3.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 49.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 49.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.20.Price to Earnings Growth RatioRepligen has a PEG Ratio of 2.75. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Repligen (NASDAQ:RGEN) StockRepligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.Read More Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comWhy Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?March 19, 2023 | americanbankingnews.comRepligen (NASDAQ:RGEN) Research Coverage Started at StockNews.comMarch 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 18, 2023 | ca.finance.yahoo.comRGEN Mar 2023 220.000 callMarch 18, 2023 | sg.finance.yahoo.comRGEN Mar 2023 230.000 callMarch 14, 2023 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Receives $216.86 Consensus Target Price from AnalystsMarch 12, 2023 | seekingalpha.comRepligen: Exclusive Partnerships And Innovation Set To Drive GrowthFebruary 23, 2023 | finance.yahoo.comRepligen Corporation (NASDAQ:RGEN) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 23, 2023 | finance.yahoo.comRepligen's (RGEN) Q4 Earnings and Revenues Beat EstimatesFebruary 23, 2023 | finance.yahoo.comRepligen Full Year 2022 Earnings: EPS Beats ExpectationsFebruary 22, 2023 | finance.yahoo.comRepligen Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 20, 2023 | finance.yahoo.comWhy Repligen Corporation (NASDAQ:RGEN) Could Be Worth WatchingFebruary 9, 2023 | finance.yahoo.comRepligen Appoints Martin D. Madaus to Board of DirectorsFebruary 8, 2023 | finance.yahoo.comRepligen to Report Fourth Quarter and Full Year 2022 Financial ResultsJanuary 21, 2023 | finance.yahoo.comRepligen (NASDAQ:RGEN) stock performs better than its underlying earnings growth over last five yearsJanuary 13, 2023 | finance.yahoo.comDo Options Traders Know Something About Repligen (RGEN) Stock We Don't?January 12, 2023 | finance.yahoo.comWhy Shares of Repligen Rose This WeekJanuary 12, 2023 | finance.yahoo.comHZNP vs. RGEN: Which Stock Is the Better Value Option?January 3, 2023 | finance.yahoo.comRepligen Corporation to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 1, 2023 | reuters.comRGEN.OQ - Repligen Corp | Stock Price & Latest News | ReutersDecember 18, 2022 | seekingalpha.comRepligen: Valuation Still A Concern, No Change To Hold ThesisDecember 7, 2022 | finance.yahoo.comDespite Attractive End Markets, Analyst Outlines Concerns For Repligen StockNovember 23, 2022 | finance.yahoo.comBIIB or RGEN: Which Is the Better Value Stock Right Now?November 21, 2022 | finance.yahoo.comDeclining Stock and Decent Financials: Is The Market Wrong About Repligen Corporation (NASDAQ:RGEN)?November 7, 2022 | finance.yahoo.comBIIB vs. RGEN: Which Stock Is the Better Value Option?November 1, 2022 | finance.yahoo.comRepligen (RGEN) Q3 Earnings and Revenues Top EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Company Calendar Last Earnings2/22/2023Today3/24/2023Next Earnings (Estimated)4/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees2,025Year Founded1981Price Target and Rating Average Stock Price Forecast$216.86 High Stock Price Forecast$275.00 Low Stock Price Forecast$180.00 Forecasted Upside/Downside+36.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$3.25 Trailing P/E Ratio48.74 Forward P/E Ratio60.01 P/E Growth2.75Net Income$185.96 million Net Margins23.20% Pretax Margin27.34% Return on Equity10.31% Return on Assets7.68% Debt Debt-to-Equity RatioN/A Current Ratio2.47 Quick Ratio1.88 Sales & Book Value Annual Sales$801.54 million Price / Sales10.98 Cash Flow$3.96 per share Price / Cash Flow40.04 Book Value$34.41 per share Price / Book4.60Miscellaneous Outstanding Shares55,560,000Free Float54,952,000Market Cap$8.80 billion OptionableOptionable Beta1.09 Social Links Key ExecutivesTony J. HuntPresident, Chief Executive Officer & DirectorJames R. BylundChief Operating OfficerJon K. SnodgresChief Financial & Accounting OfficerRalf KuriyelSenior Vice President-Research & DevelopmentVikas GuptaVP & GM-Downstream Bioprocessing & Gene TherapyKey CompetitorsNeurocrine BiosciencesNASDAQ:NBIXExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOSeagenNASDAQ:SGENBiogenNASDAQ:BIIBView All CompetitorsInsiders & InstitutionsVictory Capital Management Inc.Sold 77,771 shares on 3/10/2023Ownership: 0.069%North Star Asset Management Inc.Bought 2,544 shares on 3/6/2023Ownership: 0.157%Teachers Retirement System of The State of KentuckyBought 800 shares on 2/22/2023Ownership: 0.015%Northwestern Mutual Investment Management Company LLCSold 2,674 shares on 2/21/2023Ownership: 0.009%B. Riley Wealth Advisors Inc.Sold 58 shares on 2/21/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions RGEN Stock - Frequently Asked Questions Should I buy or sell Repligen stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks. What is Repligen's stock price forecast for 2023? 7 equities research analysts have issued 1-year target prices for Repligen's shares. Their RGEN share price forecasts range from $180.00 to $275.00. On average, they predict the company's share price to reach $216.86 in the next year. This suggests a possible upside of 36.9% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts. How have RGEN shares performed in 2023? Repligen's stock was trading at $169.31 at the beginning of the year. Since then, RGEN stock has decreased by 6.4% and is now trading at $158.42. View the best growth stocks for 2023 here. When is Repligen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023. View our RGEN earnings forecast. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) posted its quarterly earnings results on Wednesday, February, 22nd. The biotechnology company reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.10. The biotechnology company earned $186.80 million during the quarter, compared to analysts' expectations of $184.41 million. Repligen had a trailing twelve-month return on equity of 10.31% and a net margin of 23.20%. The business's revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.81 earnings per share. What ETFs hold Repligen's stock? ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco Dynamic Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG), WisdomTree BioRevolution Fund (WDNA) and Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC). What guidance has Repligen issued on next quarter's earnings? Repligen issued an update on its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share guidance of $2.61-$2.69 for the period, compared to the consensus EPS estimate of $2.92. The company issued revenue guidance of $760.00 million-$800.00 million, compared to the consensus revenue estimate of $800.22 million. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." Who are Repligen's major shareholders? Repligen's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.13%), Sands Capital Management LLC (3.21%), WCM Investment Management LLC (2.89%), Artisan Partners Limited Partnership (2.10%), Macquarie Group Ltd. (1.98%) and Alliancebernstein L.P. (1.94%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $158.42. How much money does Repligen make? Repligen (NASDAQ:RGEN) has a market capitalization of $8.80 billion and generates $801.54 million in revenue each year. The biotechnology company earns $185.96 million in net income (profit) each year or $3.25 on an earnings per share basis. How many employees does Repligen have? The company employs 2,025 workers across the globe. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115. This page (NASDAQ:RGEN) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.